April 15, 2019
JUPITER, FL / ACCESSWIRE / April 15, 2019 / Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of bio...
April 8, 2019
NEW YORK, April 8, 2019 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, announced that the presentations from the April 4th, 2019 conference are now available for on-demand viewing at VirtualInvestorConferences.com.
April 1, 2019
JUPITER, Fla., April 1, 2019 /PRNewswire/ -- Dyadic International, Inc. (the "Company") (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to speed up the development, lower production costs and improve the performance of biol...
March 28, 2019
NEW YORK, March 28, 2019 /PRNewswire/ -- Virtual Investor Conferences today announced the agenda for the upcoming Virtual lnvestor Conference, the leading proprietary investor conference series.  Individual investors, institutional investors, advisors and analysts are invited to attend. Th...
March 27, 2019
JUPITER, FL / ACCESSWIRE / March 27, 2019 / Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of bio...
March 25, 2019
JUPITER, FL / ACCESSWIRE / March 25, 2019 / Dyadic International, Inc. (the "Company") (OTCQX: DYAI), today announced that its President and Chief Executive Officer, Mark Emalfarb and Chief Accounting Officer, Ping Rawson will be presenting at the following three upcoming investor conferences:
March 13, 2019
JUPITER, FL / ACCESSWIRE / March 13, 2019 / Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to speed up the development, lower production costs and improve the performance of biologic v...
March 11, 2019
LOS ANGELES, CA / ACCESSWIRE / March 11, 2019 / Dyadic International (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and lower the cost of biologic vaccines and drugs at flexible commercia...
February 25, 2019
JUPITER, FL / ACCESSWIRE / February 25, 2019 / Dyadic International, Inc. (the ''Company'') (OTCQX: DYAI), today announced that its President and Chief Executive Officer, Mark Emalfarb, will be presenting at the following two upcoming investor conferences:
February 13, 2019
JUPITER, FL / ACCESSWIRE / February 13, 2019 / Dyadic International, Inc. (the "Company") (OTCQX: DYAI) today announced that the Securities and Exchange Commission (the "SEC") has declared the Company's Registration Statement on Form 10-12G (the "Form 10") effective as of February 12, 2019. As a res...